Folotyn (pralatrexate) / Mundipharma, Aurobindo, CASI, Assertio - LARVOL DELTA

Rare cancer, rare survivors: A 20-year single-center review of adult T-cell lymphoma/leukemia treatment outcomes (ASH 2025) - "Among acute ATLL pts (n=25), initial therapy included CHOP or CHOEP (40%), hyperCVAD (28%), and Zidovudine + interferon a (AZT+IFN) (20%)...Among lymphomatous subtypes pts (n=24), the majority received CHOP-based regimens initially (79%), followed by salvage with ICE, pralatrexate, or romidepsin...A small number of long-term survivors were observed in acute ATLL with limited tumor burden in the lymph node involvement, associated with early use of AZT+IFN, followed by mogamulizumab, or AlloHCT...Unfortunately, we currently lack highly effective frontline treatment options, which makes consolidative strategies such as transplantation difficult to execute. These findings underscore the urgent need for earlier recognition, subtype-adapted therapy, and suggest the incorporation of antiviral and immune-based strategies to improve ATLL outcomes."

Clinical • Review • Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Endocrine Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy (ASH 2025) - "Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) has been the standard initial therapy for PTCL; however, clinical outcomes remain suboptimal. The introduction of brentuximab vedotin (BV)-CHP has improved survival in CD30-positive PTCL patients (pts) and has become the standard therapy for this subgroup...Of the 33 pts who subsequently received salvage therapy, 22 received at least one novel agent (e.g., BV, romidepsin, pralatrexate, tucidinostat), and 19 received conventional chemotherapy... PTCL pts who achieved CR after initial therapy demonstrated favorable long-term survival. However, more than half experienced relapse, with no clear plateau in relapse risk. This finding indicates a continued risk of relapse and highlights the need for long-term monitoring."

Clinical • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

The NLP protein is a novel regulator of G2-m Phase of the cell cycle critical for proliferation of human peripheral T-cell lymphomas (ASH 2025) - "Standard regimens such as CHOP or R‑CHOP, along with approved targeted agents(belinostat, romidepsin, pralatrexate), have yielded limited long‑term benefit, with 5‑year survival rates ofonly 20–30%...Homozygous NLP knockout mice are viable butshow ~10% reduction in the body size suggesting that mouse NLP is important but not essential fornormal development.Altogether, our findings identify NLP as a novel regulator of the G2–M phase of the cell cycle with acritical role in the proliferation of malignant T-cells. Given its predicted druggable structure, NLPrepresents a promising candidate for the development of novel targeted PTCL therapies."

Hematological Malignancies • Liver Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Renal Cell Carcinoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • ATF5 • BRCA1 • CHEK2 • EPAS1 • RPL10

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study) (ASH 2025) - P2 | "Background First-line (1L) therapy for peripheral T-cell lymphoma (PTCL) is cyclophosphamide, doxorubicin, vincristineand prednisone (CHOP)-based, and relapse/refractory (r/r) rates are high (75%) with limited therapeuticoptions thereafter; currently approved agents for r/r PTCL include belinostat and pralatrexate, withoverall response rates (ORR) of <30% and progression free survival (PFS) between 2-4 months. To our knowledge, this study is thefirst to explore a novel oral targeted agent for newly diagnosed pts with a subtype specific PTCL. Thechemotherapy de-escalation and response-adapted design will potentially identify pts who may benefitfrom no chemotherapy or novel agent plus chemotherapy combination."

Clinical • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • JAK1

Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma (ASH 2025) - "We have shownthat DNMT3 inhibitors like 5-azacytidine have potent immunomodulatory effects, including upregulationof cancer testis antigens, in pre-clinical models of T-cell lymphoma. We successfully identified the RP2D for DAC and/or PTX in combination with pembro inpatients with R/R PTCL and CTCL. We demonstrated that an epigenetic platform incorporating theimmune checkpoint inhibitor pembrolizumab is safe in heavily pretreated disease. More work onchanges in cytokine profiles is needed before drawing any conclusions on their relationship to response."

Clinical • Combination therapy • Adult T-Cell Leukemia-Lymphoma • Cutaneous T-cell Lymphoma • Febrile Neutropenia • Heart Failure • Hematological Malignancies • Immune Modulation • Immunology • Lymphoma • Neutropenia • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • IL10 • TNFA

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL) (ASH 2025) - P1, P3 | "Introduction ITK is expressed in T cells and NK cells and is involved in multiple signaling pathways including T cellreceptor (TCR) activation and differentiation of T helper (Th) cells. Thesefindings indicate that the mechanism of action involves the induction of a host anti-tumor immuneresponse that requires a baseline level of immunocompetence. These data suggest that effectivetherapeutic strategies for these lymphomas should extend beyond direct targeting of malignant T cells.SQL is now being evaluated vs standard therapy (belinostat or pralatrexate) in a randomized Phase 3registration trial in PTCL pts with 1-3 prior therapies (NCT06561048)."

Clinical • IO biomarker • P1 data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Pruritus • CD4 • CD8 • GATA3 • HAVCR2 • IFNG • IL2 • ITK • LAG3 • TNFA

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study. (ASH 2025) - P=N/A | "First-line (1L)systemic regimens were predominantly a) immunomodulatory agents (n=47, 29.3%); including oralretinoid (n=20), extracorporeal photopheresis (n=18), interferon (n=9) followed by b) chemotherapy(n=30, 18.7%) and c) targeted therapies (n=17, 10.6%) including Brentuximab Vedotin (n=6), Romidepsin(n=5), Mogamulizumab (n=3), Vorinostat (n=2) and Pralatrexate (n=1). We present initial data from our prospective LEO-MER cohort, a large US-based multicenter consortia.Our findings demonstrate variability in both diagnostic staging and treatment approaches for MF/SSpatients. The cohort demonstrated worse outcomes with high-risk disease and Black race/ethnicity.These findings warrant further study on the impact of underlying social determinant factors, given thevariability noted in this population."

Clinical • Real-world • Real-world evidence • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD4

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan (ASH 2025) - P | "The median TTNT of each SA after 2nd- or later-linetherapies (mo, 95% CI) was 10.7 (3.9–17.3) for brentuximab vedotin (BV; n = 53, 21%), 5.0 (2.7–7.1) fortucidinostat (n = 36, 14%), 3.9 (2.6–4.8) for romidepsin (n = 80, 31%), 2.1 (0.4–5.2) for darinaparsin (n = 7,3%), 1.8 (1.3–2.5) for pralatrexate (n = 58, 23%), 1.5 (0.6–NE) for forodesine (n = 8, 3%), 1.1 (0.4–2.4) formogamulizumab (n = 22, 9%), 0.7 (0.4–3.5) for denileukin diftitox (n = 5, 2%), and NR (NE–NE) for alectinib(n = 1, 0.4%). In patients with TFHL, romidepsin (44%) and tucidinostat (18%) yielded median TTNTs (mo,95% CI) of 4.0 (2.6–8.7) and 5.5 (1.9–7.8), respectively... To the best of our knowledge, this study reports the most recent treatment patterns andprognoses for patients with R/R MTNKL. No standard of care has been established, as diverse treatmentpatterns have been observed. SAs resulted in similar survival outcomes to CCs in 2nd-line therapy,despite distinctive clinical Background of the groups."

Clinical • Observational data • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Dermatology • Extranodal Natural Killer/T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas (ASH 2025) - "Supportive care, including leucovorin, was provided per institutional standards.Dose-limiting toxicities (DLTs) were defined as grade ≥4 hematologic or grade ≥3 non-hematologictreatment-related adverse events, with protocol-specified exceptions, occurring during the first twocycles of therapy. Furthermore,the ORR observed with this combination was lower than historical benchmarks for pralatrexatemonotherapy, which may be attributable to the reduced pralatrexate dosing in this study and potentialdirect growth stimulation of malignant T cells by pembrolizumab. Given the limited efficacy and safetyconcerns, further development of this regimen as studied is not warranted."

Cutaneous T-cell Lymphoma • Dermatology • Follicular Lymphoma • Hypertension • Lymphoma • Mycosis Fungoides • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders (ASH 2025) - "Patients were grouped by treatment:those offered cytotoxic chemotherapy, romidepsin, pralatrexate, or alemtuzumab were assigned togroup 1, and all others were assigned to group 0.Sequencing was performed on skin biopsies using whole exome DNA, whole transcriptome RNA, andusing a targeted gene panel.Results79 patients with skin biopsies showing CD30+ T cell LPD were included. Increased proliferativesignaling and MYC-driven transcriptional programs are associated with high risk disease, and an increasein resting dendritic cells in lesional skin is associated with low risk disease. Future studies are needed forvalidation of these findings for prognostication."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • B2M • BCOR • BIRC3 • CUL1 • EPHB1 • ERO1A • GNAS • IL2RA • JAK3 • KDR • KIF23 • NBN • NCOR2 • PRDM1 • PRKDC • SSBP1 • TET2 • TGFBR2 • TNFRSF8

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov) - P3 | N=218 | Recruiting | Sponsor: Dizal Pharmaceuticals

New P3 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. (PubMed, bioRxiv) - "Simulated clinical trials predicted that biomarker-guided patient selection could improve the power to detect significant benefit of adding pralatrexate to frontline chemotherapy in PTCL. These findings illustrate how the causal insights of functional genetic screens can augment correlative studies to identify biomarkers of drug response, and suggest the potential for precise use of pralatrexate for PTCL."

Journal • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Anti-Inflammatory Response to Anti-Folate and Vitamin D Analog Combination in Large Granular Lymphocyte Leukemia (ASH 2023) - "Instead, it is treated when symptoms arise with a variety of immunosuppressive therapies, chief among them, the anti-folate, methotrexate (MTX)...Pralatrexate (PDX) is a more potent analog of MTX, not yet utilized in LGL leukemia...Taken together, these data suggest a strong single agent potency for PDX and an anti-inflammatory benefit to MTX/PDX and EB1089 combination. Continued mechanistic study of the anti-folate/vitamin D receptor agonist pairing as well as further investigation into PDX's impact on LGLs will be crucial to follow up investigations."

Anemia • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Neutropenia • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • PTPN2

C17ORF58 Is Upregulated in Peripheral T-Cell Lymphomas and Encodes a Protein Critical for Survival of PTCL Cells (ASH 2023) - "Despite the increase in specific T-cell lymphoma treatment options, such as belinostat, romidepsin, pralatrexate, and brentuximab vedotin, alongside conventional non-targeted chemotherapy like CHOP and R-CHOP, the overall 5 year survival remains only at 20-30%. In conclusion, our data indicate that upregulation of C17ORF58 may contribute to the progression and maintenance of PTCL and could serve as a potential target for treating T-cell malignancies. Investigations into its physiological role in normal T-cells and pathways deregulated upon its inactivation are ongoing."

B Cell Lymphoma • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • COL1A2 • MYBL2 • PAX2 • TRIP13

Cerebral Spinal Fluid Attenuates the Efficacy of Methotrexate Against Acute Lymphoblastic Leukemia Cells (ASH 2023) - "While this was confirmed for several ALL drugs including cytarabine and anthracyclines, we strikingly found that methotrexate was significantly less efficacious and potent against ALL cells in CSF relative to standard tissue culture media or the more physiologically relevant human plasma-like media (HPLM). CSF also attenuated the sensitivity of ALL cells to other anti-folates including raltitrexed, trimetrexate, and pralatrexate...Activation of the UPR with thapsigargin, a sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor that triggers ER stress, increased methotrexate resistance in leukemia cells...Moreover, we anticipate that our current work defining the mechanisms driving this resistance may identify novel approaches for maximizing methotrexate efficacy and more completely eradicating leukemia cells in CSF and the CNS. Finally, this work highlights the importance of critically evaluating even long-established standards of care."

Clinical • Acute Lymphocytic Leukemia • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo (ASH 2024) - P3 | "We anticipate enrolling 504 patients who meet the inclusion criteria : 18yrs with newly diagnosed, previously untreated PTCL (including PTCL-NOS, angioimmunoblastic T-cell lymphoma, ALK- negative ALCL [for which brentuximab vedoitin (Bv) cannot be used due to unavailability or tolerance], follicular T cell lymphoma and others [extra-nodal natural killer/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; and subcutaneous panniculitis-like T-cell lymphoma]) based on local pathology review, with measurable disease, ECOG performance status ≤2, and eligible to receive Bel or Fol, and a standard CHOP regimen (cyclophosphamide 750 mg/m2 IV, Day 1; doxorubicin 50 mg/m2 IV, Day 1; vincristine 1.4 mg/m2 (maximum 2 mg) IV, Day 1; and prednisone 100 mg daily PO, Days 1–5). Tumor assessments will be performed every 3 cycles and end-of-treatment visit, then every 3 months for 3 years for patients with CR, PR or SD, and every 6..."

Clinical • P3 data • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Lymphoma • Mucositis • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

An Anti-Apoptotic Protein C17ORF58 Is Critical for the Maintenance of Human Peripheral T-Cell Lymphomas By Suppressing BBC3-Induced Apoptosis (ASH 2024) - "Despite treatments with conventional chemotherapy like CHOP and R-CHOP, as well as targeted therapies such as belinostat, romidepsin, pralatrexate, and brentuximab vedotin, the overall 5-year survival rate remains low at 20-30%. Consistently, C17ORF58 knockdown in T-cell lines results in the upregulation of numerous pro-apoptotic genes, including BBC3 (PUMA), EPAS1, ATF5, DUSP8, S100A6, and CHAC1. Importantly, shRNA-mediated knockdown of BBC3 suppresses apoptosis induced by C17ORF58 loss of function, suggesting that BBC3 is a key downstream target negatively regulated by C17ORF58.Altogether, our data suggest that C17ORF58 is an anti-apoptotic protein exerting its activity by suppressing BBC3-induced apoptosis, presenting a potential novel target for improving PTCL therapies."

Clinical • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ATF5 • BBC3 • CHAC1 • DNMT3A • EPAS1 • S100A6

Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics (ASH 2024) - "The cohort received distinct but heterogeneous frontline treatments that included SMILE (n=4), CHOEP (n=1), DeVIC (n=3), MTX/Asp/Dex (n=1), cisplatinum with radiotherapy (n=2), and palliative radiation therapy (n=1)...Overall, 3 patients underwent second-line treatment, with GemOx (n=1), Brentuximab Vedotin (n=1), and SMILE (n=1), achieving PR (n=2) and PD (n=1). Third and fourth-line treatments included romidepsin (n=1), palliative chemotherapy (n=1), cytotoxic T-lymphocytes on a clinical trial (n=1) and pralatrexate (n=1)...The extensive insights gained from cell co-localization and cell-cell communication signals will prioritize novel biomarkers that underlie responsiveness to chemotherapy. Correlative multi-omic analyses with genomic alterations and HLA specificity in a first-of-its-kind multiregional and highly multiplexed cohort are underway and will be reported at the meeting."

Biomarker • Clinical • Tumor microenvironment • Epstein-Barr Virus Infections • Hematological Malignancies • Infectious Disease • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • CD8

Patterns of Care and Impact of Initial Treatment in Peripheral T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (MER) Prospective Cohort Study (ASH 2023) - P=N/A | "The most common 1st line chemotherapy regimens overall were CHOP-based (N=506, 70%), including 60% receiving CHOP-like chemotherapy in both MER and LEO cohorts (CHOP [N=268, 37%], CHOEP [N=91, 13%] or EPOCH [N=75, 10%]), and 16% with CHOP-like in combination with novel agents in LEO cohort (BV+ [N=41, 9.3%], azacitidine+ [N=11, 2.5%], pralatrexate+ [N=10, 2.3%], lenalidomide+ [N=8, 1.9%]) (Table 1)...Outcomes continue to mature with longitudinal follow-up and ongoing accrual, which poise to shape benchmarks in the contemporary era. The lack of benefit of etoposide adding to CHOP induction and poor overall survival of non-ALCL subtypes underscores the unmet need of therapeutic breakthrough for non-ALCL frontline treatment, particularly through clinical trials with biomarker-guided approaches incorporating novel agents."

Clinical • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

A Retrospective Study of Extracorporeal Photopheresis (ECP) in Treatment of Cutaneous T-Cell Lymphoma (CTCL) Evaluating Global, Skin and Blood Responses (ASH 2023) - "Besides, ECP techniques including the administration of methoxsalen have changed...At 3 months 28 pts were on ECP alone and 11 were on concurrent systemic therapy including: Interferon (4), retinoid acid (3), romidepsin (3), and pralatrexate (1). At 6 months 20 pts were on ECP alone and 19 were on concurrent systemic therapy including interferon (7), retinoid acid (4), Romidepsin (4), and 1 patient for each of mogamulizumab, vorinostat, methotrexate and interferon + retinoid acid... A total of 39 pts were included. 23 (59%) were male; 31 (82%) were Caucasian, 4 (11%) were African-American. When starting ECP, 33 (89%) had stage III/IV disease; 30 (77%) had erythroderma; 10.3%, 33.3% and 56.4% of pts had B0, B1 and B2 disease, respectively (Table 1)."

Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Pruritus • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data (ASH 2023) - P1, P2 | "To further develop novel-lacutamab combinations, the combinability of lacutamab with therapies used in R/R or frontline PTCL e.g., pralatrexate or CHOP, respectively, was tested. These data inform the future development of lacutamab to provide additional therapeutic options that may improve outcomes for PTCL patients, including those who relapse or are refractory to available therapies. A Phase 2 study evaluating the combination of lacutamab with GemOx is ongoing (NCT04984837) based on pre-clinical observations that GemOx improves lacutamab-induced ADCC by NK cells."

Clinical data • Monotherapy • Preclinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • KIR3DL2

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas (ASH 2024) - "Three (38%) and 2 (25%) SPTCL patients transitioned to bexarotene and cyclosporine maintenance therapy after achieving a CR with pralatrexate, respectively. Conclusions Pralatrexate is effective and associated with durable responses in cytotoxic CTCL. Upon disease relapse, retreatment with pralatrexate was effective with high rates of second complete remissions observed in SPTCL."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CD8 • GZMB

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Transplantation • CD33

Subcutaneous panniculitis-like T-cell lymphoma complicated by hemophagocytic syndrome with significant response to pralatrexate: A case report. (PubMed, JAAD Case Rep) - No abstract available

Journal • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of pralatrexate combined with chidamide and azacitidine in adult patients with newly diagnosed peripheral T-cell lymphoma (ChiCTR) - P2 | N=20 | Not yet recruiting | Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

New P2 trial • Follicular Lymphoma • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma